Atai Beckley N.V. (ATAI)

Market Cap	842.35M
Revenue (ttm)	3.02M
Net Income (ttm)	-154.19M
Shares Out	214.34M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,877,651
Open	3.880
Previous Close	3.960
Day's Range	3.720 - 4.000
52-Week Range	1.150 - 6.750
Beta	1.60
Analysts	Strong Buy
Price Target	14.00 (+256.23%)
Earnings Date	Nov 12, 2025

About ATAI

Atai Beckley N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizoph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: ATAI
• Website: https://www.ataibeckley.com

Financial Performance

In 2024, Atai Beckley's revenue was $308,000, a decrease of -1.91% compared to the previous year's $314,000. Losses were -$149.27 million, 271.1% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price target is $14.0, which is an increase of 256.23% from the latest price.

Price Target

$14.0

(256.23% upside)

Analyst Consensus: Strong Buy